Goldman Sachs is set to boost its mergers and acquisitions ranking after acting for US pharmaceuticals company Johnson & Johnson on its $12.3bn (€13.7bn) acquisition of Alza.
Although Johnson & Johnson declined to give the names of its advisers, sources close to Goldman Sachs privately confirm that the bank acted on the transaction.